top of page
This site was designed with the
.com
website builder. Create your website today.Start Now

ARINDAM TALUKDAR, Ph. D.

Talukdar's lab, lead by Dr. Arindam Talukdar, a Sr. Principal Scientist in CSIR Indian Institute of Chemical Biology, primarily deals with medicinal chemistry. It aims to answer the fundamental questions lying at the interface of chemistry and biology by integrating the concept of organic chemistry, biochemistry and computational explorations for the design and synthesis of novel chemical entities to unravel the molecular mechanism and develop potential treatments for human diseases.​

​

1200px-ResearchGate_icon_SVG.svg.png

  1. Hit-to-lead optimization of 2-aminoquinazolines as anti-microbial agents against Leishmania donovani. Das N, Roy J, Patra B, Saunders E, Sarkar D, Goon S, Sinha BP, Roy S, Roy S, Sarif J, Bandopadhyay P, Barik S, Mukherjee S, McNamara N, Varghese S, Simpson K, Baell J, McConville M, Ganguly D, Arindam Talukdar. European Journal of Medicinal Chemistry. 2024, 269, 116256. 
    https://doi.org/10.1016/j.ejmech.2024.116256
     

  2. Discovery and Development of Quinazolinones and Quinazolinediones for Ameliorating Nonalcoholic Fatty Liver Disease (NAFLD) by Modulating COP1-ATGL Axis. Sarkar D, Chowdhury S, Goon S, Sen A, Dastidar UG, Mondal MA, Chakrabarti P, Arindam Talukdar. Journal of Medicinal Chemistry. 2023, 66, 24, 16728. https://doi.org/10.1021/acs.jmedchem.3c01431
     

  3. ​Editorial: Catalyzing the Future of Medicinal Chemistry Research in India. Arindam Talukdar*, Sarkar D. Journal of Medicinal Chemistry (Editorial), 2023, 66, 16, 10868. 
    https://doi.org/10.1021/acs.jmedchem.3c01304.
     

  4. Development of selective class I protein arginine methyltransferase inhibitors through fragment-based drug design approach.  Bhattacharya D, Shi Ming Li A, Paul B, Ghosh Dastidar U, Santhakumar V, Sarkar D, Chau I, Li F, Ghosh T, Vedadi M, Arindam Talukdar*. European Journal of Medicinal Chemistry, 2023, 260, 115713. https://doi.org/10.1016/j.ejmech.2023.115713.
     

  5. Mitigating hERG Liability of Toll-Like Receptor 9 and 7 Antagonists through Structure-Based Design. Das N, Bhattacharya D, Bandyopadhyay P, Ghosh Dastidar U, Paul B, Rahaman O, Hoque I, Patra B, Ganguly D*, Arindam Talukdar*. ChemMedChem, 2023, Jun 15;18(12):e202300069 (ASAP) https://doi.org/10.1002/cmdc.202300069. 

bottom of page